Spruce Biosciences price target raised to $259 from $254 at Citizens JMP

Citizens JMP raised the firm’s price target on Spruce Biosciences (SPRB) to $259 from $254 and keeps an Outperform rating on the shares. Spruce remains on track to submit its biologics license application for Tralesinidase Alfa Enzyme Replacement Therapy for Sanfilippo Syndrome Type B in 1Q26, the analyst tells investors in a research note. The firm is impressed with management’s execution since its acquisition of TA-ERT.